Kazerounian Shideh, Lawler Jack
The Department of Pediatrics, Division of Genetics and Genomics, Boston Children's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
The Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 02215, USA.
J Cell Commun Signal. 2018 Mar;12(1):171-179. doi: 10.1007/s12079-017-0433-3. Epub 2017 Dec 20.
Angiogenesis or neovascularization is a complex multi-step physiological process that occurs throughout life both in normal tissues and in disease. It is tightly regulated by the balance between pro-angiogenic and anti-angiogenic factors. The angiogenic switch has been identified as the key step during tumor progression in which the balance between pro-angiogenic and anti-angiogenic factors leans toward pro-angiogenic stimuli promoting the progression of tumors from dormancy to dysplasia and ultimately malignancy. This event can be described as either the outcome of a genetic event occurring in cancer cells themselves, or the positive and negative cross-talk between tumor-associated endothelial cells and other cellular components of the tumor microenvironment. In recent years, the mechanisms underlying the angiogenic switch have been extensively investigated in particular to identify therapeutic targets that can lead to development of effective therapies. In this review, we will discuss the current findings on the regulatory pathways in endothelial cells that are involved in the angiogenic switch with an emphasis on the role of anti-angiogenic protein, thrombospondin-1 (TSP-1) and pro-angiogenic factor, vascular endothelial growth factor (VEGF).
血管生成或新生血管形成是一个复杂的多步骤生理过程,在正常组织和疾病状态下的整个生命过程中都会发生。它受到促血管生成因子和抗血管生成因子之间平衡的严格调控。血管生成开关已被确定为肿瘤进展过程中的关键步骤,在此过程中,促血管生成因子和抗血管生成因子之间的平衡倾向于促血管生成刺激,从而促进肿瘤从休眠状态发展为发育异常并最终发展为恶性肿瘤。这一事件既可以被描述为癌细胞自身发生的基因事件的结果,也可以被描述为肿瘤相关内皮细胞与肿瘤微环境中其他细胞成分之间的正负相互作用。近年来,人们对血管生成开关背后的机制进行了广泛研究,特别是为了确定能够开发有效治疗方法的治疗靶点。在这篇综述中,我们将讨论目前关于内皮细胞中参与血管生成开关的调控途径的研究结果,重点关注抗血管生成蛋白血小板反应蛋白-1(TSP-1)和促血管生成因子血管内皮生长因子(VEGF)的作用。